Trial Profile

Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations: A Single-arm, Phase II Multi-center Trial

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lazertinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms LU21-16

Most Recent Events

12 Sep 2023 Status changed from not yet recruiting to recruiting, as per Results presented at the 24th World Conference on Lung Cancer
12 Sep 2023 Results (data cut-off of Mar 31st, 2023, n=32), presented at the 24th World Conference on Lung Cancer
17 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com